Forward P/S Multiple: Intelligent Bio Solutions Inc (INBS)
Intelligent Bio Solutions is facing a liquidity shortage and a need for borrowed funds. The projected P/S metric on GURU.Markets reflects expectation dynamics, where the indicator level stands at 1.40. This underscores the value of the company's unique non-invasive sweat tests, although concerns regarding certification rigor and potential lawsuits over diagnostic accuracy act as headwinds.
Summary analytical data breakdowns for ibs.inc (INBS)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Intelligent Bio Solutions|INBS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Intelligent Bio Solutions Inc.|INBS - Company Aggregate Debts|Debt to Book Capitalization Ratio INBS|INBS - Company Long-Term Debt|Company Current Liabilities Intelligent Bio Solutions|Quick Ratio ibs.inc
- financial results and valuation multiples details:
INBS - Company Net Income|Expected Profit Intelligent Bio Solutions|INBS - Market Cap to Net Income Ratio|Projected Price to Earnings Intelligent Bio Solutions Inc.|INBS - PEG Multiple|EV/EBITDA Multiple INBS|INBS - Operating income before deduction of amortization|Earnings per share for the last twelve months Intelligent Bio Solutions|INBS - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months ibs.inc|INBS - Net earnings per share growth this year|Earnings growth forecast for next year Intelligent Bio Solutions
- sales and revenue indicators:
Fundamental company analysis:INBS (Intelligent Bio)
Investors are finding it difficult to balance current stock volatility with long-term revenue growth prospects. Analyzing the forward price-to-sales chart allows for the determination of the deviation of market value from expected earnings, which is critical for Intelligent Bio Solutions (INBS), as its capitalization currently depends directly on successful FDA certification to scale rapid testing in the US market.
Who Intelligent Bio Solutions competes with
Price-to-Projected Revenue Ratio Dexcom DXCM|PEN - Forward Price-to-Revenue Multiple|Novanta Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Haemonetics Company|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED) - Forward P/S Multiple|Pulse Biosciences Inc (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward Price-to-Revenue Multiple Picard Group PMI|Forward P/S Multiple SRDX (Surmodics, Inc.)|Forward P/S Multiple senseonics.com SENS|NPCE - Price-to-Projected Revenue Ratio|TCMD: Price-to-Projected Revenue Ratio|SNWV (SANUWAVE Health, Inc.) - Forward Price-to-Revenue Multiple|Outset Medical Corp - Forward Price to Sales|ELMD (SmartVest) - Forward P/S Multiple|Market Cap to Future Revenue Ratio lensar.com LNSR|Price-to-Projected Revenue Ratio AVITA Medical (RCEL)|profoundmedical.com (PROF) - Projected Price to Revenue|Baird Medical - Forward Price-to-Revenue Multiple|Forward P/S Multiple EDAP TMS SA EDAP|Bovie Medical - Forward P/S Multiple|Market Cap to Expected Sales Ratio IceCure Medical Ltd ICCM|pulmonx.com (LUNG) - Price-to-Projected Revenue Ratio|Future Price to Revenue TELA (TELA Bio)|Price-to-Projected Revenue Ratio CytoSorbents Corp|Forward Price-to-Revenue Multiple Sensus (SRTS)|Forward P/S Multiple ZYXI|ECOR - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Vicarious Surgical RBOT|IINN: Market Cap to Projected Revenue|ICU: Forward Price-to-Revenue Multiple|IRIDEX Corporation - Price to Expected Revenue Ratio|XAIR: Forward P/S Multiple|PFSA - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio STRATA Skin Sciences Inc.|Market Cap to Projected Revenue GCTK (glucotrack.com)|Forward Price-to-Revenue Multiple NAOV (NanoVibronix)|Price to Expected Revenue Ratio VERO|Forward P/S Multiple NUWE (Nuwellis, Inc.)|aethlonmedical.com (AEMD) - Market Cap to Future Revenue Ratio|ASXC - Price-to-Projected Revenue Ratio|AVGR: Price-to-Projected Revenue Ratio|BioSig Technologies, Inc (BSGM) - Price-to-Projected Revenue Ratio|CUTR (Cutera Inc) - Price-to-Projected Revenue Ratio|KNW (Know Labs, Inc.) - Forward P/S Multiple|inarimedical.com (NARI) - Market Cap to Expected Sales Ratio|Forward P/S Multiple NVRO|reshapelifesciences.com (RSLS) - Projected Price to Revenue|Forward P/S Multiple SILK (Silk Road Medical Inc.)
